glycopyrronium

The drug is intended for the maintenance therapy of adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) if other combination therapies do not provide sufficient effect.

Form: inhalation, suspension under pressure

ATC: R03AL11

Manufacturer: AstraZeneca Dunkerque Production (manufacturing, primary packaging, secondary packaging, quality control and batch release)